Dysbiosis leading to abnormal intestinal fermentation has been suggested as a possible etiological mechanism in irritable bowel syndrome (IBS). We aimed to investigate the location and magnitude of altered intestinal bacterial fermentation in IBS and its clinical subtypes.
INTRODUCTION
Irritable bowel syndrome (IBS) is characterized by chronic or recurring abdominal pain or discomfort associated with altered bowel habits and is one of the most common gastrointestinal (GI) disorders ( 1, 2 ) . IBS is considered a multifactorial disorder associated with visceral hypersensitivity, altered gut motility, and dysfunction of the brain-gut axis and immune system. However, the pathophysiology of the disorder is still not completely understood (2) (3) (4) (5) . Recently, it has been suggested that alterations in the gut microbiota, leading to abnormal intestinal fermentation, may be a possible etiological mechanism (6) (7) (8) (9) .
Intestinal fermentation by gut microbiota is a central physiological process by which polymers, including carbohydrates, are biotransformed into end-products, mainly short-chain fatty acids (SCFAs) and gases. Th ese intraluminal fermentation processes have an important role in supplying nutrients and energy to the host ( 10 ) . However, alterations in intestinal fermentation may lead to certain physiological abnormalities that are oft en Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome observed in IBS such as intraluminal excessive gas production and altered motility. Th ese alterations in intestinal physiology can be an important factor in provoking or exacerbating IBS symptoms ( 11, 12 ) . In addition, interventional clinical studies targeting the intestinal microbiota with antibiotics or probiotics demonstrated benefi cial eff ects in some patients with IBS ( 13, 14 ) . Specifi cally, in regard to intestinal fermentation, recent studies have shown that a diet low in FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) can off er considerable symptom relief in patients with IBS ( 15, 16 ) . However, the role of altered intestinal fermentation by intestinal bacteria in the pathogenesis of IBS has not been adequately investigated in this condition.
We hypothesized that bacterial fermentation is altered in certain segments of the GI tract in IBS and that these alterations are associated with bowel functions and symptoms. Th e aims of the current study were to investigate the location and magnitude of altered intestinal bacterial fermentation in IBS and its clinical subtypes and to examine their relation to bowel characteristics and GI symptoms. Intestinal fermentation was assessed by measuring intraluminal pH levels (by a wireless motility capsule (SmartPill; Given Imaging, Yoqneam, Israel)) and fecal SCFAs concentration as surrogate markers in a cohort of well-characterized patients with IBS and healthy controls (HC).
METHODS

Study population
All subjects were recruited from the University of North Carolina (UNC) healthcare outpatient clinics and from the Chapel Hill general population by advertising. Inclusion criteria included age of 18 years or older, any gender, race, or ethnicity. HCs had no chronic or recurring GI symptoms. IBS patients met the Rome III criteria for IBS and had mild-to-moderate symptom severity with the IBS-symptom severity scale (IBS-SSS) score of 175-300. Additional inclusion criteria included normal physical examination and laboratory tests and a normal colonoscopy within the last 3 years, in patients aged 50 years or older. Subjects with a history of GI tract surgery (other than appendectomy or cholecystectomy), a history of infl ammatory bowel diseases, celiac disease, lactose malabsorption, or any other diagnosis that could explain their chronic or recurrent bowel symptoms were excluded from the study. In addition, participants were excluded if they had a history of treatment with antibiotics, anti-infl ammatory agentsincluding aspirin, non-steroidal anti-infl ammatory drugs or steroids, or intentional consumption of probiotics in the past 6 weeks. All subjects were evaluated by a physician to exclude an alternative diagnosis to IBS. Th e study was approved by the UNC internal review board, and all subjects provided written consent before participation and were compensated for participating in the study.
Clinical symptom assessments in IBS
Abdominal pain/discomfort, altered bowel habit (loose/watery or hard/lumpy stools), and bloating were assessed using a 10-cm visual analogue scale (maximum score, 10) ( 17 ). IBS-SSS ( 18 ) and IBS-specifi c quality-of-life (IBS-QOL) ( 19 ) were also assessed. Stool frequency was measured by the number of bowel movements per day and stool consistency determined using the Bristol Stool Scale ( 20 ) .
Assessment for intraluminal fermentation and intestinal transit
Intestinal fermentation was assessed using two surrogate markers: intestinal intraluminal pH and fecal SCFAs. Intraluminal pH levels were measured using a wireless motility capsule (SmartPill). Th e wireless motility capsule is an FDA approved device that is clinically used to assess intestinal transit. Aft er being swallowed, the capsule constantly measures intraluminal pH, pressure, and temperature as it travels through the GI tract and transmits this information wirelessly to a portable receiver worn by the examinee ( 21 ) . Using these parameters and a specifi c software, the (SmartPill) system generates data on gastric emptying time, small bowel transit time (SBTT), colon transit time (CTT), and whole-gut transit time (WGTT) ( 21, 22 ) . For the purpose of this study, we used the intraluminal pH data as surrogate markers for intestinal fermentation. To enable further accuracy in assessment of localization of intestinal fermentation, the small and large bowel pH measurements were both divided into four quartiles (Q1-4) based on the total time in each (small and large bowel) segment. SBTT, CTT, and WGTT were also assessed as previously described ( 21, 22 ) .
Analysis of SCFA
Fresh stool samples were collected from all subjects on site or at home in the morning of the study visit. Each fecal sample was immediately transferred to the laboratory where it was homogenized and stored at −80 °C until analyzed. Fecal acetate, propionate, butyrate, lactate, and total SCFAs were quantifi ed in fecal samples in duplicate using capillary gas chromatography with 2-ethyl butyric acid as an internal standard, as described previously ( 10, (23) (24) (25) .
Statistical analysis
We used Student's t -test when there were two groups being compared and analysis of variance when there were more than two groups being compared for continuous variables. Th e χ 2 test was used for discrete variables. For post hoc analysis, Tukey's honest signifi cance test was used. Baseline characteristics were evaluated by Student's t -test or Pearson's χ 2 test. Intestinal pH, fecal SCFA levels, and GI transit times were compared between groups by Student's t -test or analysis of variance. Correlations between colonic pH, fecal SCFAs, CTT, stool frequency and consistency, IBS-SSS, and IBS-QOL were performed using Spearman's correlation analysis for all study subjects including IBS and HC. All P -values were twotailed, and P -values<0.05 were considered statistically significant. Statistical analyses were performed using SPSS version 18.0 for Windows (SPSS, Chicago, IL, USA). Unless otherwise stated, data are presented as mean±s.d.
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RESULTS
Study population
We investigated a total of 147 subjects (114 IBS and 33 HC). Th e study IBS population included patients with constipation-predominant IBS (C-IBS, n =26), diarrhea-predominant IBS (D-IBS, n =42), mixed type IBS (M-IBS, n =32), and unspecifi ed type IBS ( n =14). Th e racial distribution was as follows: Caucasian 70.7%, Black 21.1%, and other 8.2%. Th ere were no signifi cant diff erences in age, sex, body mass index, and race between the study groups ( Table 1 ) .
Intestinal intraluminal pH
Intestinal intraluminal pH data were collected from 47 patients with IBS and 10 HCs. Mean total colonic pH levels were significantly lower in the IBS group compared with HC (6.8 vs. 7.3, P =0.042). Th e signifi cant diff erences were also observed in Q1 (6.4 vs. 6.8, P =0.011) and Q4 (7.2 vs. 7.8, P =0.046). Th e colonic pH levels at the Q1 were the lowest among the four quartiles in both groups ( Table 2 and Figure 1 ). Th e lower intraluminal colonic pH levels compared with HC were consistent across all IBS subtypes (mean total colonic pH: 7.0 for C-IBS, 7.0 for D-IBS, 6.8 for M-IBS, 6.4 for unspecifi ed type IBS, and 7.3 for HC, respectively; Table 3 ).
Th ere were no intraluminal pH diff erences in the four quartiles and total small bowel between IBS and HC (mean total small bowel pH: 6.8 for IBS vs. 6.8 for HC, P =0.937; Table 2 ). Also, there were no signifi cant intraluminal small bowel pH diff erences between the groups based on IBS subtypes.
In subgroup analyses, small and large bowel pH levels were not diff erent according to gender, race, and age (≤45 vs. >45).
Fecal SCFAs
Fecal SCFAs were measured in all enrolled subjects (114 IBS and 33 HC). Mean acetate, propionate, butyrate, lactate, and total fecal SCFAs levels were not significantly different between all IBS and HC (total SCFAs level: 92.1 m m vs. 92.0 m m , P =0.996, respectively). Acetate had the highest levels followed by propionate and butyrate in both IBS and HC. Lactate was not detected, except for two cases (6.4 m m in a M-IBS subject and 8.1 m m in a D-IBS subject). The SCFAs profiles were similar across the different IBS subtypes ( Table 4 and Figure 2 ). However, acetate, propionate, butyrate, and total SCFAs levels were lower in C-IBS than in all the other subtypes and were significantly lower compared with D-IBS. The propionate level in C-IBS was significantly lower than in any other group. Colonic pH levels. Quartile 1 and 4 and mean total colonic pH levels were signifi cantly lower in irritable bowel syndrome (IBS; n =47) compared with healthy control (HC; n =10). The pH in the proximal colon (quartile 1) was the lowest in both groups. * P <0.05.
FUNCTIONAL GI DISORDERS
VOLUME 110 | SEPTEMBER 2015
Ringel-Kulka et al.
Intestinal transit time
Intestinal transit time data were collected from 47 patients with IBS and 10 HCs. Overall the average intestinal transit times including SBTT, CTT, and WGTT were not signifi cantly diff erent between IBS patients and HC. However, as expected, CTT and WGTT were signifi cantly longer in C-IBS compared with those in D-IBS and M-IBS. Th ere were no signifi cant diff erences in SBTT between the groups. Th e whole-gut and segmental transit times are presented in Table 5 .
Correlation between colonic pH, fecal SCFAs, CTT, and symptoms
Colonic pH levels positively correlated with CTT (Spearman's correlation coeffi cient, SCC=0.33, P =0.013) and had a negative correlation trend with fecal SCFA levels (SCC=−0.23, P =0.079). Acetate, propionate, butyrate, and total SCFA levels correlated negatively with CTT and positively with stool frequency (total SCFAs vs. CTT, SCC=−0.44, P =0.001; total SCFAs vs. stool frequency, SCC=0.45, P <0.001).
Colonic pH levels positively correlated with IBS-SSS (SCC=0.49, P =0.014), and similar positive trends were noted for abdominal pain and bloating with negative trends for IBS-QOL. CTT had correlation trend positively with IBS symptom scores and negatively with IBS-QOL. Fecal SCFA levels had no correlation with IBS symptom scores and QOL. Th e results of Spearman's correlation analyses are presented in Table 6 . Figure 2 . Fecal short-chain fatty acids (SCFAs) levels by irritable bowel syndrome (IBS) subtypes. Total SCFA level was signifi cantly lower in constipation-predominant irritable bowel syndrome (C-IBS) than in diarrhea-predominant IBS (D-IBS), mixed type IBS (M-IBS), and healthy control (HC). Total SCFA level averaged across all IBS was similar with that in HC. Propionate level in C-IBS was signifi cantly lower than that of the other groups. Acetate and butyrate levels were signifi cantly lower in C-IBS than in D-IBS. * P <0.05. U-IBS, unspecifi ed type IBS.
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logical mechanisms underlying the disease remain unknown. Recently, the possible role of the intestinal microbiota in the pathogenesis of IBS has gained much interest ( 4, 8, 26 ) . In this study, we investigated the role of intestinal bacterial fermentation in IBS.
DISCUSSION
IBS is a common condition that aff ects nearly 10% of the general population ( 1,2 ) and contributes to a signifi cant decrease in QOL along with an increase in health-care utilization. In spite of its high prevalence and impact on QOL, the pathophysio- 
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Intraluminal intestinal fermentation by colonic bacteria produces gases such as hydrogen and carbon dioxide and SCFAs as secondary by-products ( 10, 27, 28 ) . Th e predominant SCFAs produced by bacterial fermentation are acetate, butyrate, and propionate. Lactate, which is a precursor for propionate and butyrate, is itself a by-product of fermentation. SCFAs are naturally acidic and cause a measurable drop in the pH of the intestinal lumen (28) (29) (30) . In this study, we have measured intraluminal pH levels and fecal SCFA concentrations as surrogate markers for intraluminal intestinal fermentation and used these factors to assess the location and magnitude of intestinal bacterial fermentation in a well-characterized cohort of patients with IBS and HC.
We found that the mean total colonic pH levels were signifi cantly lower in IBS compared with HC, potentially indicating higher intraluminal bacterial fermentation in the IBS group. Of great importance is our fi nding of consistently higher bacterial fermentation in the large bowel of patients with IBS compared with HC, whereas there were no diff erences in the pH levels in the small bowel between those two groups. Notably, these fi ndings were consistent in all small bowel and large bowel segments and across all IBS subtypes.
Th e intraluminal pH levels were lower at the proximal colon than the distal colon in both IBS and HC groups when we divided the quartiles based on the transit time. However, the quartiles based on transit time might not be the same as those based on geography, because if some patients might have mixtures of very rapid transit through one part of the colon and then very slow transit through the next, although these two segments might diff er pathophysiologically. Although those cases were not considered common fi ndings, it may be a limitation of our study.
Small intestinal bacterial overgrowth (SIBO) is a condition in which an excess of colonic bacteria colonize the small intestine. Th e symptoms of SIBO and IBS overlap ( 31 ) , and it has been suggested that the prevalence of SIBO is increased in IBS or that SIBO may have an etiological role in the pathogenesis of IBS, particularly in view of the improvement of symptoms with antibiotic treatment (32) (33) (34) (35) . However, the link between SIBO and IBS is still unclear, and there are some controversies regarding the real prevalence and the importance of SIBO in the pathogenesis of IBS ( 36 ) . Our study fi ndings indicate an increased bacterial fermentation in the large but not in the small bowel of patients with IBS, thus supporting the hypothesis of altered microbial composition and/or function in the colon rather than in the small bowel (e.g., in SIBO) in the pathogenesis of IBS. In addition, our fi nding of signifi cant diff erences in total and segmental CTT, but not in SBTT between IBS and its subtypes and HC, further supports the importance of altered colonic rather than small bowel physiology in the pathogenesis of the disorder.
Th e importance of SCFAs as possible etiological factors in the pathogenesis of IBS is suggested by observations from animal and human studies. Animal studies demonstrate that SCFA can initiate high-amplitude propagated colonic contractions ( 37 ) and accelerated intestinal transit and motility via intestinal release of 5-hydroxytryptamine ( 38 ) . Intracolonic infusion of 0.5% acetic acid enhanced sensitivity to colorectal distension ( 39 ) . In a human study, the total concentration of SCFAs in jejunal secretion was approximately four times higher in patients with SIBO than in healthy subjects ( 40 ) . In addition, a recent study reported higher counts of acetic-and propionic-acid producing bacteria ( Veillonella and Lactobacillus ) in IBS patients and an association between the higher levels of these SCFAs and GI symptoms and QOL ( 41 ) . However, the studies in this area have generated confl icting fi ndings on fecal organic acids. For example, a study conducted in patients with D-IBS showed that fecal SCFAs were decreased compared with HC ( 42 ). In our study, there were no signifi cant diff erences in the mean levels of fecal SCFAs between IBS (all subtypes) and HC, and the levels of fecal SCFAs did not correlate with IBS symptom severity. However, we were able to demonstrate that fecal SCFAs levels in C-IBS patients were signifi cantly lower than those in D-IBS patients and tended to be lower than those in all the other IBS subtypes and HC. In addition, as expected, SCFAs levels negatively correlated with CTT, which is consistent with our fi nding of a positive correlation between colonic pH and CTT, indicating that higher fermentation with higher production of SCFA is associated with increased motility and shorter transit times. An alternative explanation can be reduced absorption of SCFAs in patients with rapid intestinal transit due to a shorter transit time. Th e diffi culties in interpretation of these fi ndings refl ect the multifactorial determinants of fecal SCFAs. Intraluminal SCFAs are very effi ciently absorbed in the colon, and only 5 to 10% of the SCFAs produced by bacterial fermentation are excreted and can be measured in the stool (43) (44) (45) . Th e correlation between fecal SCFAs levels and CTT and the diff erences between IBS subtypes suggest that fecal SCFAs levels may be controlled by CTT more dominantly than fermentation degree; thus, fecal SCFAs may not be a sensitive marker to estimate intraluminal bacterial fermentation.
In addition to magnitude and location, we examined the associations between intestinal fermentation and clinical presentation of IBS. Unlike what we expected, the colonic pH levels positively correlated with IBS symptom scores including IBS-SSS. Th is fi nding suggests that other factors such as abnormal intestinal motility and psychological disturbances may be more important than bacterial fermentation in determining symptoms severity.
Th e wireless motility SmartPill capsule measures pH, pressure, and temperature in real-time throughout the GI tract ( 21 ) . Overall, pH profi les in the GI tract are characterized by an abrupt rise in pH from acid to near neutral as the capsule exited the stomach, a slow continued rise in pH through the small bowel until reaching the large bowel where pH falls more than 1 unit, and subsequently there is a slow rise in pH through the colon ( 21, 46 ) . Th e pH drop at the ileocecal junction is well documented in studies using ingestible radiotelemetry capsules ( 47, 48 ) . Time between an abrupt rise of pH in duodenum and a fall of >1 pH unit in ileocolonic junction was taken as SBTT. CTT was assessed by measuring the time required from cecal entry to body exit (loss of signal and/or an abrupt temperature drop) ( 21 ) . A recent scintigraphic study using a radioisotope-labeled WMC has validated this pH change at the ileocolonic junction and has shown that the fall in pH observed with WMC corresponds to the time of arrival of the WMC into the cecum or ascending colon ( 49 ) . Several studies have confi rmed the utility of WMC in quantifying CTT when compared with
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Alterations in the gut microbiota have a role in irritable bowel syndrome (IBS).
✓ Alterations in intestinal fermentation lead to certain physiological abnormalities such as intraluminal excessive gas production and altered motility.
✓ Diet low in fermentation substrates such as poorly absorbable, highly fermentable carbohydrates offers considerable symptom relief in IBS. the radiopaque marker method. Th ere was a good agreement between the WMC and radiopaque marker transit results ( 22, 46 ) . Th e WMC is a validated test; however, there are some confounding issues with the test. Th e pH drop at the ileocecal junction is occasionally (<5%) not clearly identifi able, and device failure is reported in <3% of cases. In our study, the pH landmarks were well identifi ed in all cases, and there were no capsule failures.
To our knowledge, there has been no previous study to evaluate bacterial fermentation in the whole intestine by assessing intraluminal pH changes in patients with IBS. However, our study may have some limitations. First, although subjects were asked to keep their regular diet during the study, we did not have a detailed dietary data and could not control for dietary eff ects on intestinal physiology and fermentation processes including intraluminal pH and SCFA production. Second, we did not investigate the intestinal bacterial community, so we do not know which bacterial species or genera were altered and how these alterations relate to the variables of interest. Th ird, we did not evaluate gas production, such as hydrogen and methane, which might be associated with symptom generation. Finally, the analyses of the wireless motility capsule (SmartPill) data included a relatively small number of subjects and involved some multiple comparisons, particularly in the sub-analysis by IBS subtypes. Further large-scale studies, including the analyses of dietary factors, gas production, and bacterial communities are needed. Th ese studies may enable to associate alterations in bacterial fermentation with specifi c diet or bacterial communities and provide insights on how these associations relate to the altered physiology and symptoms observed in IBS.
In conclusion, we found that colonic intraluminal pH is decreased, suggesting increased bacterial fermentation, in IBS patients across all subtypes compared with HC, and that this process is more prominent in the proximal colon. Th e altered intestinal fermentation and transit in IBS appear to be in the colon and not in the small bowel. Higher levels of fecal SCFAs and lower levels of intraluminal pH are associated with decreased CTT. Th e hypothesized model of our study results was illustrated in the Figure 3 . Our study further supports the notion that altered colonic bacterial fermentation has an important etiological role for in the pathogenesis of IBS. Future studies should investigate the degree to which altered intestinal fermentation is a cause of IBS symptoms or an eff ect of IBS-related altered physiology by, if possible, direct measurement of bacterial fermentation and clarify the possible clinical benefi t of targeting intestinal fermentation in the treatment of functional GI disorders.
